BRAF and cancer: Even more intriguing is the possibility that, through this mechanism, trametinib and cobimetinib, alone or combined with BRAF inhibitors, might sustain the activation of the anti-cancer-specific immune response, including enhanced recruitment of dendritic cells and lymphocytes due to sustained chemokine release.